Personalised medicine: the next leap forward for health care?

As health care becomes more competitive, companies are securing an advantage through personalised medicine development.

2020 M12 18

15 minutes

Joanna Tucka
As health care becomes more competitive, companies are securing an advantage through personalised medicine development.

The fast view

  • Personalised therapies offer better outcomes for patients and a potential revolution in health care.
  • We expect immunotherapy and gene therapy to facilitate these therapies.
  • Artificial intelligence and new drug development techniques create the potential for both incumbents and new entrants to take market share.
  • The COVID-19 pandemic has spurred many of these trends: expediting vaccine research; encouraging remote monitoring of trials; and increasing the use of telemedicine.
  • Health care remains highly competitive, with many existing therapeutic areas becoming more crowded.
  • We believe innovative companies that have a diverse product mix and participate in new areas of development are better placed to succeed.
  • These trends emphasise the importance of taking a global approach to identifying winners and losers.

Health care’s rapid transformation

The impressive speed with which the world has been able to develop a vaccine for COVID-19 and the potential implications of the use of messenger RNA technology1 in a range of therapies illustrate the rapid developments underway in medical technology. In particular, the idea that each of us could have our treatments tailored more closely to our unique needs, genetic make-up (genomics) and individual lifestyle. Personalised medicine could radically change health outcomes for us as patients.

Given their transformative potential, we analyse these developments as part of our in-depth fundamental research, as they are changing the face of pharma and allowing companies to secure a competitive advantage. We aim to uncover such investment opportunities through our 4Factor framework.

Health care is a truly global sector. Picking winners and losers therefore requires a global view. Only with that perspective is it possible to differentiate companies based on current and future product focus. With this in mind, this viewpoint looks at companies across the globe, including those we own and those we don't, to provide a comprehensive view of the competitive health care landscape.

Download PDF


1 Messenger RNA (mRNA) is genetic material involved in the production of proteins that can be effective in fighting viruses or mutations.

Road to 2030: Technological disruption

Widespread technological disruption in multiple fields continues to challenge traditional industries and create new products. We think of technology not as a series of objects but as an enabler of the increasing abundance of goods and services, as well as transformations in the workplace, mobility and healthcare.

Read more

Authored by

Joanna Tucka
4Factor analyst

Wichtige Informationen

Diese Mitteilung dient lediglich der allgemeinen Information und ist nicht als Beratung zu verstehen.

Alle darin enthaltenen Informationen gelten als zuverlässig, können jedoch ungenau oder unvollständig sein. Die Ansichten sind die des Verfassers zum Zeitpunkt der Veröffentlichung und spiegeln nicht unbedingt die Ansichten von Ninety One wider.

Alle geäußerten Meinungen werden ehrlich vertreten. Diese sind jedoch nicht garantiert und somit sollte sich auf diese nicht verlassen werden